Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ubenimex in Pulmonary Arterial Hypertension
NCT02736149Phase 2Terminated
- Sponsor
- Eiger BioPharmaceuticals, Inc.
- Start
- Dec 2016
- Primary completion
- Mar 2018
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ubenimex in pulmonary arterial hypertension (PAH), sponsored by Eiger BioPharmaceuticals, Inc.. Started Dec 2016; status: terminated.
02
Drugs
ubenimex
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02736149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02736149.